Abbott (NYSE:ABT) announced today that the FDA approved its Aveir single-chamber (VR) leadless pacemaker for slow heart rhythms.
In November 2021, the Abbott Park, Illinois-based company reported results from an FDA investigational device exemption (IDE) study that showed that Aveir met pre-specified primary endpoints in patients with certain abnormal heart rhythms, suggesting that, if approved, Aveir could aid those who require the use of a pacemaker to treat slow heart rhythms.